The Tenth Circuit stated that, to date, the court has not adopted a benchmark percentage for attorneys’ fees and declines to do so—instead, the court said that awards in a range of percentages may be reasonable.
The plaintiffs in the underlying case are shareholders in Array Biopharma. According to the opinion, those shareholders brought a federal securities class action claim against Array and its executives and alleged that the defendants made deliberate statements about a clinical trial resulting in significant shareholder losses.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
